Journal Article
. 2021 Aug; 23(1):83.
doi: 10.1186/s13058-021-01448-1.

Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer

Jessica Castrillon Lal 1 Madeline G Townsend 1 Anita K Mehta 1 Madisson Oliwa 1 Eric Miller 2 Alaba Sotayo 3 Emily Cheney 1 Elizabeth A Mittendorf 1 Anthony Letai 3 Jennifer L Guerriero 4 
Affiliations
  • PMID: 34353349
  •     79 References

Abstract

Background: The heterogeneity of the breast tumor microenvironment (TME) may contribute to the lack of durable responses to immune checkpoint blockade (ICB); however, mouse models to test this are currently lacking. Proper selection and use of preclinical models are necessary for rigorous, preclinical studies to rapidly move laboratory findings into the clinic.

Methods: Three versions of a common syngeneic model derived from the MMTV-PyMT autochthonous model were generated by inoculating 1E6, 1E5, or 1E4 cells derived from the MMTV-PyMT mouse into wildtype recipient mice. To elucidate how tumor latency and TME heterogeneity contribute to ICB resistance, comprehensive characterization of the TME using quantitative flow-cytometry and RNA expression analysis (NanoString) was performed. Subsequently, response to ICB was tested. These procedures were repeated using the EMT6 breast cancer model.

Results: The 3 syngeneic versions of the MMTV-PyMT model had vastly different TMEs that correlated to ICB response. The number of cells used to generate syngeneic tumors significantly influenced tumor latency, infiltrating leukocyte populations, and response to ICB. These results were confirmed using the EMT6 breast cancer model. Compared to the MMTV-PyMT autochthonous model, all 3 MMTV-PyMT syngeneic models had significantly more tumor-infiltrating lymphocytes (TILs; CD3+, CD4+, and CD8+) and higher proportions of PD-L1-positive myeloid cells, whereas the MMTV-PyMT autochthonous model had the highest frequency of myeloid cells out of total leukocytes. Increased TILs correlated with response to anti-PD-L1 and anti-CTLA-4 therapy, but PD-L1expression on tumor cells or PD-1 expression of T cells did not.

Conclusions: These studies reveal that tumor cell number correlates with tumor latency, TME, and response to ICB. ICB-sensitive and resistant syngeneic breast cancer models were identified, in which the 1E4 syngeneic model was most resistant to ICB. Given the lack of benefit from ICB in breast cancer, identifying robust murine models presented here provides the opportunity to further interrogate the TME for breast cancer treatment and provide novel insights into therapeutic combinations to overcome ICB resistance.

Keywords: Breast cancer; Immune checkpoint blockade; Immunotherapy; Jessica Castrillon Lal and Madeline G. Townsend contributed equally to this work; Preclinical mouse models; Syngeneic tumor models.

Breast Cancer Immunotherapy: Facts and Hopes.
Leisha A Emens.
Clin Cancer Res, 2017 Aug 13; 24(3). PMID: 28801472    Free PMC article.
Highly Cited. Review.
CRI iAtlas: an interactive portal for immuno-oncology research.
James A Eddy, Vésteinn Thorsson, +9 authors, Justin Guinney.
F1000Res, 2020 Nov 21; 9. PMID: 33214875    Free PMC article.
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation.
G Solinas, G Germano, A Mantovani, P Allavena.
J Leukoc Biol, 2009 Sep 11; 86(5). PMID: 19741157
Highly Cited. Review.
CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.
Debbie C Strachan, Brian Ruffell, +4 authors, Dylan Daniel.
Oncoimmunology, 2014 Feb 06; 2(12). PMID: 24498562    Free PMC article.
Highly Cited.
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
Rituparna Das, Rakesh Verma, +8 authors, Kavita M Dhodapkar.
J Immunol, 2014 Dec 30; 194(3). PMID: 25539810    Free PMC article.
Highly Cited.
TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer.
Álvaro de Mingo Pulido, Alycia Gardner, +5 authors, Brian Ruffell.
Cancer Cell, 2018 Jan 10; 33(1). PMID: 29316433    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Scott J Antonia, José A López-Martin, +21 authors, Emiliano Calvo.
Lancet Oncol, 2016 Jun 09; 17(7). PMID: 27269741
Highly Cited.
Management of cutaneous melanoma.
Hensin Tsao, Michael B Atkins, Arthur J Sober.
N Engl J Med, 2004 Sep 03; 351(10). PMID: 15342808
Highly Cited. Review.
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858804    Free PMC article.
Highly Cited. Review.
CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.
Koji Kono, Hiromichi Kawaida, +5 authors, Hideki Fujii.
Cancer Immunol Immunother, 2005 Dec 06; 55(9). PMID: 16328385
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, +16 authors, IMpassion130 Trial Investigators.
N Engl J Med, 2018 Oct 23; 379(22). PMID: 30345906
Highly Cited.
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.
Jo Vandesompele, Katleen De Preter, +4 authors, Frank Speleman.
Genome Biol, 2002 Aug 20; 3(7). PMID: 12184808    Free PMC article.
Highly Cited.
Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model.
Ana C Gregório, Nuno A Fonseca, +5 authors, João Nuno Moreira.
PLoS One, 2016 Nov 08; 11(11). PMID: 27820870    Free PMC article.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Macrophage diversity enhances tumor progression and metastasis.
Bin-Zhi Qian, Jeffrey W Pollard.
Cell, 2010 Apr 08; 141(1). PMID: 20371344    Free PMC article.
Highly Cited. Review.
A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
Thomas Powles, Shah-Jalal Sarker Foreshew, +14 authors, Simon Chowdhury.
Eur J Cancer, 2014 Jun 09; 50(12). PMID: 24908540
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.
David G DeNardo, Jairo B Barreto, +4 authors, Lisa M Coussens.
Cancer Cell, 2009 Aug 04; 16(2). PMID: 19647220    Free PMC article.
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Elizabeth Allen, Arnaud Jabouille, +8 authors, Gabriele Bergers.
Sci Transl Med, 2017 Apr 14; 9(385). PMID: 28404866    Free PMC article.
Highly Cited.
Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1.
M E Fuentes, S K Durham, +5 authors, S A Lira.
J Immunol, 1995 Dec 15; 155(12). PMID: 7499865
Highly Cited.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Javier Cortes, David W Cescon, +18 authors, KEYNOTE-355 Investigators.
Lancet, 2020 Dec 07; 396(10265). PMID: 33278935
Targeting the CCL2-CCR2 signaling axis in cancer metastasis.
Su Yin Lim, Arseniy E Yuzhalin, Alex N Gordon-Weeks, Ruth J Muschel.
Oncotarget, 2016 Feb 18; 7(19). PMID: 26885690    Free PMC article.
Highly Cited. Review.
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, +7 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295    Free PMC article.
Highly Cited.
Dendritic cells that phagocytose apoptotic macrophages loaded with mycobacterial antigens activate CD8 T cells via cross-presentation.
Patricia Espinosa-Cueto, Alejandro Magallanes-Puebla, Carlos Castellanos, Raul Mancilla.
PLoS One, 2017 Aug 03; 12(8). PMID: 28767693    Free PMC article.
Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.
Leandro M Colli, Mitchell J Machiela, +3 authors, Stephen J Chanock.
Cancer Res, 2016 May 20; 76(13). PMID: 27197178    Free PMC article.
Highly Cited.
Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages.
Kelly Kersten, Seth B Coffelt, +11 authors, Karin E de Visser.
Oncoimmunology, 2017 Sep 19; 6(8). PMID: 28919995    Free PMC article.
Targeting macrophages: therapeutic approaches in cancer.
Luca Cassetta, Jeffrey W Pollard.
Nat Rev Drug Discov, 2018 Oct 27; 17(12). PMID: 30361552
Highly Cited. Review.
Immune Checkpoint Blockade in Cancer Therapy.
Michael A Postow, Margaret K Callahan, Jedd D Wolchok.
J Clin Oncol, 2015 Jan 22; 33(17). PMID: 25605845    Free PMC article.
Highly Cited. Review.
Genomic characterization of metastatic breast cancers.
François Bertucci, Charlotte K Y Ng, +25 authors, Fabrice André.
Nature, 2019 May 24; 569(7757). PMID: 31118521
Highly Cited.
Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer.
Yue Wang, Xiaokai Zhang, +2 authors, Guangrui Hu.
J Bone Oncol, 2018 Jun 13; 11. PMID: 29892522    Free PMC article.
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.
David L Rimm, Gang Han, +8 authors, Lajos Pusztai.
Breast Cancer Res, 2019 Jun 15; 21(1). PMID: 31196152    Free PMC article.
Gene expression markers of Tumor Infiltrating Leukocytes.
Patrick Danaher, Sarah Warren, +7 authors, Steven P Fling.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239471    Free PMC article.
Highly Cited.
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Andrew A Davis, Vaibhav G Patel.
J Immunother Cancer, 2019 Oct 28; 7(1). PMID: 31655605    Free PMC article.
Highly Cited.
CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages.
Takanori Kitamura, Bin-Zhi Qian, +6 authors, Jeffrey W Pollard.
J Exp Med, 2015 Jun 10; 212(7). PMID: 26056232    Free PMC article.
Highly Cited.
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
David Cella, Viktor Grünwald, +10 authors, Robert J Motzer.
Lancet Oncol, 2019 Jan 20; 20(2). PMID: 30658932    Free PMC article.
Highly Cited.
CTLA-4 can function as a negative regulator of T cell activation.
T L Walunas, D J Lenschow, +5 authors, J A Bluestone.
Immunity, 1994 Aug 01; 1(5). PMID: 7882171
Highly Cited.
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Stephen J Luen, Roberto Salgado, +8 authors, Sherene Loi.
Lancet Oncol, 2016 Dec 15; 18(1). PMID: 27964843    Free PMC article.
Highly Cited.
Pathway level analysis of gene expression using singular value decomposition.
John Tomfohr, Jun Lu, Thomas B Kepler.
BMC Bioinformatics, 2005 Sep 15; 6. PMID: 16156896    Free PMC article.
Highly Cited.
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
David G DeNardo, Donal J Brennan, +12 authors, Lisa M Coussens.
Cancer Discov, 2011 Nov 01; 1(1). PMID: 22039576    Free PMC article.
Highly Cited.
A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer.
Daniel P Hollern, Eran R Andrechek.
Breast Cancer Res, 2014 Jul 30; 16(3). PMID: 25069779    Free PMC article.
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.
Carlos R Gil Del Alcazar, Sung Jin Huh, +27 authors, Kornelia Polyak.
Cancer Discov, 2017 Jun 28; 7(10). PMID: 28652380    Free PMC article.
Highly Cited.
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Michael J Overman, Sara Lonardi, +17 authors, Thierry André.
J Clin Oncol, 2018 Jan 23; 36(8). PMID: 29355075
Highly Cited.
Extending survival with chemotherapy in metastatic breast cancer.
Joyce O'Shaughnessy.
Oncologist, 2005 Dec 22; 10 Suppl 3. PMID: 16368868
Highly Cited. Review.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, +18 authors, Weiping Zou.
Nat Med, 2004 Aug 24; 10(9). PMID: 15322536
Highly Cited.
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
David J Messenheimer, Shawn M Jensen, +6 authors, Bernard A Fox.
Clin Cancer Res, 2017 Sep 01; 23(20). PMID: 28855348    Free PMC article.
Highly Cited.
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.
Dong-Ming Kuang, Qiyi Zhao, +4 authors, Limin Zheng.
J Exp Med, 2009 May 20; 206(6). PMID: 19451266    Free PMC article.
Highly Cited.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Scott J Antonia, Augusto Villegas, +31 authors, PACIFIC Investigators.
N Engl J Med, 2018 Oct 04; 379(24). PMID: 30280658
Highly Cited.
Coinhibitory Pathways in Immunotherapy for Cancer.
Susanne H Baumeister, Gordon J Freeman, Glenn Dranoff, Arlene H Sharpe.
Annu Rev Immunol, 2016 Mar 02; 34. PMID: 26927206
Highly Cited. Review.
Complexity and challenges in defining myeloid-derived suppressor cells.
Vera Damuzzo, Laura Pinton, +4 authors, Susanna Mandruzzato.
Cytometry B Clin Cytom, 2014 Dec 17; 88(2). PMID: 25504825    Free PMC article.
Review.
Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.
Elaine Y Lin, Joan G Jones, +4 authors, Jeffrey W Pollard.
Am J Pathol, 2003 Oct 28; 163(5). PMID: 14578209    Free PMC article.
Highly Cited.
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.
Bin-Zhi Qian, Jiufeng Li, +6 authors, Jeffrey W Pollard.
Nature, 2011 Jun 10; 475(7355). PMID: 21654748    Free PMC article.
Highly Cited.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, +30 authors, James Larkin.
N Engl J Med, 2017 Sep 12; 377(14). PMID: 28889792    Free PMC article.
Highly Cited.
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Jennifer L Guerriero, Alaba Sotayo, +11 authors, Anthony Letai.
Nature, 2017 Mar 09; 543(7645). PMID: 28273064    Free PMC article.
Highly Cited.
Breast Cancer Treatment: A Review.
Adrienne G Waks, Eric P Winer.
JAMA, 2019 Jan 23; 321(3). PMID: 30667505
Highly Cited. Review.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.
Martina Schmittnaegel, Nicolò Rigamonti, +8 authors, Michele De Palma.
Sci Transl Med, 2017 Apr 14; 9(385). PMID: 28404865
Highly Cited.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Michael J Overman, Ray McDermott, +13 authors, Thierry André.
Lancet Oncol, 2017 Jul 25; 18(9). PMID: 28734759    Free PMC article.
Highly Cited.
Myeloid-derived suppressor cells coming of age.
Filippo Veglia, Michela Perego, Dmitry Gabrilovich.
Nat Immunol, 2018 Jan 20; 19(2). PMID: 29348500    Free PMC article.
Highly Cited. Review.
Lessons in signaling and tumorigenesis from polyomavirus middle T antigen.
Michele M Fluck, Brian S Schaffhausen.
Microbiol Mol Biol Rev, 2009 Sep 02; 73(3). PMID: 19721090    Free PMC article.
Review.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Regulatory T cells, tumour immunity and immunotherapy.
Weiping Zou.
Nat Rev Immunol, 2006 Mar 25; 6(4). PMID: 16557261
Highly Cited. Review.
Antigen-specific activation of effector macrophages by IFN-gamma producing (TH1) T cell clones. Failure of IL-4-producing (TH2) T cell clones to activate effector function in macrophages.
R D Stout, K Bottomly.
J Immunol, 1989 Feb 01; 142(3). PMID: 2464024
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, +9 authors, L Norton.
N Engl J Med, 2001 Mar 15; 344(11). PMID: 11248153
Highly Cited.
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.
C T Guy, R D Cardiff, W J Muller.
Mol Cell Biol, 1992 Mar 01; 12(3). PMID: 1312220    Free PMC article.
Highly Cited.
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.
Brian Ruffell, Debbie Chang-Strachan, +7 authors, Lisa M Coussens.
Cancer Cell, 2014 Dec 03; 26(5). PMID: 25446896    Free PMC article.
Highly Cited.
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.
Julianne D Twomey, Baolin Zhang.
AAPS J, 2021 Mar 08; 23(2). PMID: 33677681    Free PMC article.
Review.
Leukocyte composition of human breast cancer.
Brian Ruffell, Alfred Au, +3 authors, Lisa M Coussens.
Proc Natl Acad Sci U S A, 2011 Aug 10; 109(8). PMID: 21825174    Free PMC article.
Highly Cited.
Comparing genetically engineered mouse mammary cancer models with human breast cancer by expression profiling.
Alexander N Shoushtari, Aleksandra M Michalowska, Jeffrey E Green.
Breast Dis, 2007 Dec 07; 28. PMID: 18057542
Review.
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.
Subhra K Biswas, Alberto Mantovani.
Nat Immunol, 2010 Sep 22; 11(10). PMID: 20856220
Highly Cited. Review.
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
Evan J Lipson, Charles G Drake.
Clin Cancer Res, 2011 Sep 09; 17(22). PMID: 21900389    Free PMC article.
Highly Cited. Review.
Protein Kinase A Catalytic Subunit Is a Molecular Switch that Promotes the Pro-tumoral Function of Macrophages.
Yi Rang Na, Jung Won Kwon, +12 authors, Seung Hyeok Seok.
Cell Rep, 2020 May 14; 31(6). PMID: 32402274
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.
Nuray Gül, Liane Babes, +7 authors, Marjolein van Egmond.
J Clin Invest, 2014 Jan 17; 124(2). PMID: 24430180    Free PMC article.
Highly Cited.
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Leisha A Emens, Cristina Cruz, +16 authors, Peter Schmid.
JAMA Oncol, 2018 Sep 23; 5(1). PMID: 30242306    Free PMC article.
Highly Cited.
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
E E Vokes, N Ready, +23 authors, L Crinò.
Ann Oncol, 2018 Feb 07; 29(4). PMID: 29408986
Highly Cited.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement.
Candace Correa, Eleanor E Harris, +5 authors, Jay R Harris.
Pract Radiat Oncol, 2016 Nov 22; 7(2). PMID: 27866865
Highly Cited.
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.
A S Doane, M Danso, +4 authors, W L Gerald.
Oncogene, 2006 Feb 24; 25(28). PMID: 16491124
Highly Cited.
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, +4 authors, Jennifer A Pietenpol.
J Clin Invest, 2011 Jun 03; 121(7). PMID: 21633166    Free PMC article.
Highly Cited.